Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Fast Track Approved
View:
Comment by fredgoodwinson on Nov 23, 2020 7:25am
'A paradigm shift in medical technology..' Nice one!!!!
Comment by hilles on Nov 23, 2020 7:38am
   Important development The FDA further states that, "Intravesical instillation does not deliver the investigational drug to the upper tract or prostatic urethra; therefore, the development of disease in these areas cannot be attributed to a lack of activity of the investigational drug. Thus, sponsors can consider patients with new malignant lesions of the upper tract or ...more  
Comment by Eoganacht on Nov 23, 2020 10:07am
Great news! We're now on target to submit an application for accelerated approval one year from the time we treat our 25th patient. If all goes well, end game should be early 2022.
Comment by jicoop on Nov 23, 2020 10:09am
So Vegas 2022 may be back on for us you saying ?
Comment by Macer on Nov 23, 2020 10:13am
Interesting news. Congrats to those that have stuck this out. This is fantastic that they have been approved for this designation. Now we need to see full steam ahead on enrollement. With a FDA approval of the various Covid Vaccines in the works there may actually be hpe that we can get US sites on board and shave signficant time off the study time. An update on the retreated patients may be very ...more  
Comment by menoalittle on Nov 23, 2020 2:55pm
>> Considering a re-entry. >> Macer ah... but to avoid the 60 day wash sale rule, you'd have to wait until sometime in December for re-enty, eh? methinks you are not alone... lol.
Comment by Longholder99 on Nov 23, 2020 4:13pm
Hmmm. Give up the tax return and get in before another NR leaves you in the dust? Or hold your nose and watch your stock app at work all day praying that nothing happens until you can grab another position in a few weeks. What could really happen now anyway? I mean nobody ever buys out micro cap oncology companies for billions after they get Fast Track.approval....do they? Or nobody might maybe ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250